2022 ASCO Annual Assembly Analysis Spherical Up: Advances in Treating Genitourinary Cancers

In the yearly Analysis Spherical Up sequence, Most cancers.Internet Editorial Board participants resolution the questions, “What used to be essentially the most thrilling or practice-changing analysis to your box offered on the 2022 ASCO Annual Assembly or the 2022 Genitourinary Cancers Symposium, and what does it imply for other people with most cancers?”

On this webinar, Most cancers.Internet Forte Editors Neeraj Agarwal, MD; Timothy Gilligan, MD, FASCO; Petros Grivas, MD, PhD; and Tian Zhang, MD, talk about new and ongoing analysis in prostate most cancers, testicular most cancersbladder most cancers, and kidney most cancers.

  • An replace from the segment 2 TheraP scientific trial, which used to be finding out whether or not lutetium-177-PSMA-617 (177Lu-PSMA-617 or LuPSMA), a kind of focused radiation remedy, may just lend a hand some other people with metastatic castration-resistant prostate most cancers that grew after remedy with chemotherapy are living longer. [3:38]

  • An replace from the segment 3 ENZAMET scientific trial, which used to be comparing whether or not including enzalutamide (Xtandi), a kind of hormonal treatment known as an androgen receptor inhibitor, to androgen-deprivation treatment may just lend a hand other people with metastatic hormone-sensitive prostate most cancers are living longer. [6:44]

  • Effects from a nationwide cohort learn about out of Norway that evaluated how not unusual it’s for other people with testicular most cancers to revel in a overdue recurrence, which is when the most cancers comes again 2 to five years or extra after remedy. [11:00]

  • Effects from a learn about checking out whether or not high-dose chemotherapy is a great choice for other people with non-seminoma germ cellular tumors of the mediastinum, or middle of the chest, that go back after chemotherapy. [14:35]

  • The overall effects from the segment 2/3 QUILT-3.032 scientific trial, which used to be finding out whether or not including the immunotherapy N-803 to straightforward immunotherapy helped shrink the tumors of other people with non-muscle-invasive bladder most cancers and helped them steer clear of surgical procedure to take away the bladder. [17:46]

  • Findings from a survey getting used to increase standards to lend a hand oncologists determine which individuals with metastatic urothelial most cancers will have to steer clear of platinum-based chemotherapy. [20:57]

  • Lengthy-term effects from the segment 3 JAVELIN Bladder 100 scientific trial, which used to be comparing whether or not other people with complicated urothelial most cancers will have to obtain repairs treatment with the immunotherapy avelumab (Bavencio) following remedy with platinum-based chemotherapy. [24:18]

  • Effects from the segment 3 EVEREST scientific trial, which used to be investigating whether or not the focused treatment drug everolimus (Afinitor) may just lengthen or save you recurrence in other people with renal cellular carcinoma who’ve won surgical procedure. [27:16]

  • An research of the segment 3 CheckMate 9ER scientific trial, which used to be finding out whether or not preliminary remedy with the focused treatment mixture cabozantinib (Cabometyx) and nivolumab (Opdivo) delays most cancers expansion longer than the focused treatment sunitinib (Sutent) in other people with complicated renal cellular carcinoma. [29:52]

  • A Q&A with the knowledgeable panelists. [32:12]

Dr. Agarwal is the senior director of scientific analysis innovation on the Huntsman Most cancers Institute on the College of Utah and a 2022 Most cancers.Internet Forte Editor for Genitourinary Cancers. Dr. Gilligan is a scientific oncologist on the Cleveland Sanatorium Taussig Most cancers Institute and a 2022 Most cancers.Internet Forte Editor for Genitourinary Cancers. Dr. Grivas is a scientific oncologist on the Seattle Most cancers Care Alliance, the scientific director of the Genitourinary Cancers Program on the College of Washington, and a 2022 Most cancers.Internet Forte Editor for Genitourinary Cancers. Dr. Zhang is an affiliate professor of inside drugs on the College of Texas Southwestern Scientific Middle, a scientific oncologist on the Harold C. Simmons Complete Most cancers Middle, and a 2022 Most cancers.Internet Forte Editor for Genitourinary Cancers.

Disclosure data for this webinar’s audio system can also be discovered of their particular person biographies, which can be connected within the paragraph above.

Was once this podcast helpful? Please subscribe, charge, and assessment Most cancers.Internet Podcasts anyplace you pay attention to podcasts. This prerecorded podcast can also be listened to on-line or downloaded in your pc. A transcript may be to be had. For more info, consult with the Most cancers.Internet podcast web page.

Most cancers.Internet podcasts are edited for duration and content material.

Share Us

Inquiry Now